Clinical Trial Update: Study of Lapatinib in Breast Cancer Patients With HER-2 Non-amplified Primary Tumors and HER-2 Positive or EGFR Positive Circulating Tumor Cells [Phase 2]

View source ↗

Summary

A Phase 2 study of lapatinib in breast cancer patients with HER-2 non-amplified primary tumors and HER-2 positive or EGFR positive circulating tumor cells has b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Lapatinib (Lapatinib)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Neoplasms, Breast | Phase 2 | Status: TERMINATED